Clinical Trial: Virus Specific Immune Lymphocytes (Virus-CTL) in the Treatment of Opportunistic Viral Diseases Post Transplantation

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Phase I/II and Multicenter Trial of Virus Specific Immune Lymphocytes (Virus-CTL) in the Treatment of Opportunistic Viral Diseases Post Transplantation

Brief Summary: Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) result in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients in China. Antiviral drugs are usually used for prophylactic purposes and treatment after early detectable viral load. Unfortunately, some patients may develop resistance to antivirals. In addition to patient with HSCT, immune compromised patients may also been the targets for these opportunistic viruses. Thus in this study, the safety and efficacy of CMV and EBV specific cytotoxic T cells (CTLs) will be determined.